Antibody P504S _ AMACR α- polyclonal
- Known as:
- Antibody P504S _ AMACR α- pab
- Catalog number:
- AB04144
- Product Quantity:
- 3.0ml
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- Antibody P504S _ AMACR α- polyclonal
Related genes to: Antibody P504S _ AMACR α- polyclonal
- Gene:
- AMACR NIH gene
- Name:
- alpha-methylacyl-CoA racemase
- Previous symbol:
- -
- Synonyms:
- RACE, P504S
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-19
- Date modifiied:
- 2016-12-13
Related products to: Antibody P504S _ AMACR α- polyclonal
Related articles to: Antibody P504S _ AMACR α- polyclonal
- Renal cell carcinoma (RCC) with fibromyomatous stroma (RCC-FMS) was classified as an "emerging/provisional" entity in the 2016 WHO classification of tumors, specifically categorized as RCC with (vascular) fibromyomatous stroma. However, it was not included in the 2022 WHO classification. Renal cell carcinoma with hemangioblastoma (RCC-HB)-like features has also been reported infrequently in recent years. RCC-HB-like features and fibromyomatous stroma is quite rare, with only two reports in the literature. This report describes a rare tumor of RCC-HB-like features and fibromyomatous stroma associated with TSC1 mutations. A female patient was incidentally discovered a right renal mass during a routine physical examination conducted 2 weeks prior. Histology revealed that the tumor consisted of three distinct components: clear cell papillary renal cell tumor (CCPRCT)-like areas, fibromyomatous stroma, and HB-like areas. Immunohistochemical staining showed that the CCPRCT-like components exhibited basolateral, cup-shaped CAIX staining and were diffusely positive for AE1/AE3, CK7, and PAX-8, partially positive for AMACR/P504S, and weakly positive for CD10. The fibromyomatous stroma was positive for H-caldesmon, desmin, and SMA. In the HB-like components, α-inhibin, ERG, CD34, CAIX, and vimentin were all diffusely positive, CD10 was partially positive, and PAX-8 showed scattered, weak positivity. Whether RCC-HB features and fibromyomatous stroma can be regarded as a distinct subtype of RCC remains to be discussed by accumulation of more cases. - Source: PubMed
Publication date: 2026/08/23
Yao ShiyunHuang JinghuiWang MingfaQuan Chunji - Metanephric adenoma (MA) is a rare benign renal neoplasm characterized by recurrent BRAF V600E mutations in ∼80% to 90% of cases. The molecular drivers in BRAF V600E‑negative MAs remain poorly understood, although rare kinase fusions have been reported. Here, we present a multi‑institutional series of 7 BRAF V600E‑negative MAs with confirmed kinase fusions. The patients included 5 women and 2 men, with a median age of 43 years (range: 24 to 62 y). All tumors were uncapsulated and exhibited typical MA histology. Notably, leaf‑like structures formed by branching dilated tubules surrounding dense small acini were observed in 4 of 7 cases, and thyroid follicle‑like structures and/or microcystic/reticular patterns were observed in 3 of 7 cases. The majority of cases showed marked paucity of edematous or fibrous stroma. By immunohistochemistry, all cases were diffusely positive for WT1 and CD57, negative for BRAF V600E (clone VE1), and largely negative for CK7 and AMACR. Targeted RNA sequencing identified fusions involving RET (CCDC6::RET in 2 cases, ANKRD26::RET in 1), ALK (STRN::ALK in 2), ROS1 (RDX::ROS1 in 1), and BRAF (CUX1::BRAF in 1). All fusions preserved the kinase domain of the respective genes. Fluorescence in situ hybridization or reverse‑transcriptase PCR confirmed the rearrangements in available cases. In contrast, targeted RNA sequencing of 7 BRAF V600E‑mutant MAs revealed no kinase fusions. All patients underwent partial nephrectomy and remained disease‑free during follow‑up (median: 18 mo, range: 14 to 115 mo). Our findings demonstrate that kinase fusions, including RET, ALK, ROS1, and BRAF, represent alternative drivers in BRAF V600E‑negative MAs, expanding the molecular spectrum of MA. In VE1-negative cases with classic MA histology, targeted RNA sequencing for these fusions may serve as a useful diagnostic adjunct. - Source: PubMed
Publication date: 2026/08/25
Zhao MingYang XiaoqunWang QifengYu WenjuanFang RongXu JiayunQiu YimiaoZhang PingHe Huiying - BACKGROUND Primary clear cell carcinoma of the colon is an exceptionally rare condition. It is still uncertain whether this carcinoma represents a separate biological category or simply a variant of typical colorectal cancer. From a diagnostic standpoint, the presence of clear cell morphology introduces significant challenges, as similar features can be observed in various other carcinomas, including renal, ovarian, and endometrial carcinoma. Typically, primary colorectal tumors demonstrate positivity for markers such as CK20 and CDX2, supporting intestinal origin. CASE REPORT We present a case of primary clear cell carcinoma of the sigmoid colon, with no adenoma component, in a 69-year-old woman. The tumor was detected on routine bowel screening colonoscopy, and the patient underwent anterior resection of a pT3N2b sigmoid tumor with prophylactic oophorectomy and salpingectomy. In contrast to the positivity for intestinal-origin markers typically seen in primary colorectal tumors, in this case, the histopathological and immunohistochemical analyses revealed that the tumor was positive for AMACR, CK7, and PAX 8 and negative for WT1, ER, PR, P16, CD10, CDX2, and CK20. These results were consistent with colonic clear cell carcinoma. CONCLUSIONS Specific data on colorectal clear cell carcinoma in Ireland and worldwide are limited. In academic literature, few cases have been documented. The presence of clear cell morphology in colon tumors presents significant diagnostic challenges, necessitating careful radiological and histopathological evaluation, which should be correlated with the patient's clinical history. This case was documented due to the extreme rarity of this condition and the diagnostic difficulties it poses, particularly in distinguishing clear cell carcinoma of the colon from conventional adenocarcinoma. - Source: PubMed
Publication date: 2026/08/07
Ahmed MohamedKhalid Abubaker K SCummins OliveRichards Kate - Renal cysts in autosomal dominant polycystic kidney disease (ADPKD) frequently harbor small intracystic epithelial proliferations that arise in continuity with the cyst lining and are distinct from other recognized proliferative lesions or well-defined renal tumors and lack a formal designation. We aim to provide the histomorphologic, immunohistochemical (IHC), and molecular characteristics of these lesions, determine their incidence, and employ the term papillary hyperplasia (PH), consistent with the recent International Society of Urological Pathology (ISUP) consensus meeting report on precursor lesions of the kidney. A multi-institutional retrospective study of nephrectomies affected by ADPKD was reviewed for PH, histomorphologic features, and clinicopathologic data. PH was defined by intracystic tufted or papillary epithelial proliferations composed of a single layer of bland cuboidal epithelial cells with minimal amphophilic to eosinophilic cytoplasm. IHC stains and molecular analysis using whole-genome sequencing were performed on a subset of cases. Eighty-five nephrectomies from 48 patients demonstrated PH in 88% (75/85) of kidneys. Predominant architectural patterns were tufting (97%), papillary (72%), hobnail (72%), and micropapillary (51%). All PH exhibited low-grade nuclei without atypia, with amphophilic (95%) and/or eosinophilic cytoplasm (63%). The most well-developed PH per case measured 0.3 by 3.1 mm (mean height by width) and occurred within small cysts with an average diameter of 3 mm. PH were positive for KRT7, GATA3, L1CAM, variably positive for AMACR, and negative for CA9 and showed no definitive molecular alterations. PH are common microscopic findings in kidneys affected by ADPKD. PH show a distinct combined histomorphologic, IHC, and molecular profile. - Source: PubMed
Publication date: 2026/08/04
Tanaka Kara SWilliamson Sean RZalles NicoleWu Douglas JAkgul MahmutAl-Obaidy KhaleelChan EmilySangoi Ankur R - Morphological changes in prostate glands, assessed by Gleason grading, remain the gold standard for diagnosing prostate cancer, yet molecular biomarkers associated with gland shape are not well understood. Here, we introduce CurvSeq, a mechanomorphology-informed framework for spatial sequencing data, and CurvSee, its complementary version for proteomic and imaging datasets. These methods integrate gland boundary curvature, pocket architecture, microenvironmental composition, and molecular profiles to study morphomechanical relationships in prostate adenocarcinoma. Using five independent spatial transcriptomic and multiplexed imaging datasets, we segmented individual prostate glands, extracted gland contours, quantified local curvature and pocket-like concavities, and projected these features onto spatially resolved gene and protein measurements. In Xenium data, CurvSeq distinguished benign and GG1 glands, identifying cancer-associated genes such as PCA3 and AMACR in GG1 glands and basal, basement membrane, and mechanotransduction-associated programs in benign glands. In Visium data, a diffusion-based morphomechanical score ordered benign glands by area, circularity, pocket number, smooth muscle abundance, immune-cell proximity, and remodeling-associated genes including MMP7. In GG4 glands, CurvSeq identified neuroendocrine-like boundary regions associated with MMP7 expression, COL1A1-rich adjacent stroma, and immune-cell accumulation. Finally, CurvSee extended this framework to multiplexed protein imaging, where combined morphology and protein-expression features distinguished Gleason-associated gland states. Together, CurvSeq and CurvSee provide a quantitative framework for linking gland architecture, local microenvironment, and molecular state, showing that prostate gland morphology can be integrated with spatial omics to identify morphomechanical niches associated with cancer progression. - Source: PubMed
Publication date: 2026/07/23
Kordic IvanRivera Moctezuma Felix GAmiri Hoseyn ALiu AlanCai ShuangyiRajab Ali Mehdia NadeemBrea LourdesVenkataraman AbhijeetShi HongshunHarik LaraSulchek Todd AYu JindanCoskun Ahmet F